Emerging Markets Earnings Round Up: Sanofi And BMS (Part 6)
This article was originally published in PharmAsia News
Executive Summary
Sanofi sees China sales dip slightly in Q3, but expects sales to rebound in the next few quarters as it sets its sights on other emerging markets such as Vietnam and Africa. Bristol Myers Squibb piggybacks on brands like Baraclude and Orencia to grow deeper in China and greater Asia.
You may also be interested in...
Deals Of The Week: Sanofi/Genfar, Janssen/Astellas, Evotec/Bayer
It was an important week for Celgene, which made two cancer deals while producing data that help validate its $2.9 billion buyout of Abraxane.
Sanofi Is Composing Emerging Markets Strategy: Latest Acquisition Is Brazilian Medley For $686M
Sanofi’s acquisition of Medley, Brazil’s largest generics company, reinforces its increasingly aggressive expansion in emerging markets.
Indian Investors Turn Cautious On Compliance Concerns
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.